BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1963117)

  • 1. Potential use of new poliomyelitis vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1990; 68(5):545-8. PubMed ID: 1963117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO recommendation on potential use of new poliomyelitis vaccines.
    Ghendon Y
    Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of oral poliomyelitis vaccine: results of a WHO enquiry.
    Esteves K
    Bull World Health Organ; 1988; 66(6):739-46. PubMed ID: 3266113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine control of poliomyelitis in the 1980s.
    Sabin AB
    Yale J Biol Med; 1982; 55(3-4):383-9. PubMed ID: 7180028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and disadvantages of killed and live poliomyelitis vaccines.
    Melnick JL
    Bull World Health Organ; 1978; 56(1):21-38. PubMed ID: 307445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran.
    Rahimi P; Tabatabaie H; Gouya MM; Zahraie M; Mahmudi M; Ziaie A; Rad KS; Shahmahmudi Sh; Musavi T; Azad TM; Nategh R
    J Clin Virol; 2007 Aug; 39(4):304-7. PubMed ID: 17590391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
    Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessment of the place of inactivated poliomyelitis vaccine in national immunization programmes.
    Assaad F
    Dev Biol Stand; 1981; 47():275-82. PubMed ID: 6262152
    [No Abstract]   [Full Text] [Related]  

  • 14. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
    Friedrich F
    Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
    Aylward RB; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaccination against poliomyelitis in France. 1983 experience and new trends].
    Celers J
    Ann Pediatr (Paris); 1984 Jun; 31(6):471-5. PubMed ID: 6465800
    [No Abstract]   [Full Text] [Related]  

  • 18. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country--five years after.
    Lasch EE; Abed Y; Marcus O; Gerichter CB; Melnick JL
    Dev Biol Stand; 1986; 65():137-43. PubMed ID: 3556771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(38):996-1001. PubMed ID: 17898693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.